New pill tested for Tough-to-Treat kidney cancer
NCT ID NCT05119335
Summary
This study tested a new oral pill called NKT2152 for adults with advanced kidney cancer that had stopped responding to standard treatments. The first part aimed to find a safe and effective dose. The second part planned to see how well the pill could shrink tumors and control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
National Cancer Institute
Bethesda, Maryland, 20892-9760, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Oklahoma
Oklahoma City, Oklahoma, 73117, United States
Conditions
Explore the condition pages connected to this study.